tbuckley/cabot-search huggingface dataset:
P40-9 Continued report on the Cancer Salon at Jichi Medical University Hospital - Restart under the COVID-19 pandemic
Authors: Rie Yamamoto, Kaori Komatsuzaki, Yoshiko Kojima, Miwako Inada, Yumi Ooeda, Masaaki Inoue, Saori Chiba, Akiko Nakayama, Kiyoe Sato, Hironori Yamaguchi
Journal: Annals of Oncology (2022)
MO2-6 The current situation and issues of cancer gene panel testing in patients with unresectable pancreatic cancer
Authors: Takuo Yamai, Ikezawa Kenji, Kawamoto Yasuharu, Hirao Takeru, Higashi Sena, Maeda Shingo, Daiku Kazuma, Abe Yutaro, Urabe Makiko, Kai Yugo, Takada Ryoji, Nakabori Tasuku, Uehara Hiroyuki, Ohkawa Kazuyoshi
Journal: Annals of Oncology (2022)
P2-10 Effect of dose-dense doxorubicin and cyclophosphamide therapy (ddAC): A single-center retrospective analysis
Authors: Fumie Fujisawa, Satomi Nakajima, Takaaki Hatano, Yukiko Seto, Yasunobu Ishizuka, Hiroki Kusama, Tetsuhiro Yoshinami, Tomoyuki Ootsuka, Saki Matsui, Minako Nishio, Naohiro Nishida, Nobuyoshi Kittaka, Naotoshi Sugimoto, Toshinari Yagi, Toshihiro Kudo, Takahiro Nakayama, Yasuhiro Tamaki
Journal: Annals of Oncology (2022)
P59-2 Improved survival with neoadjuvant chemotherapy in stage III pancreatic cancer: a single institutional experience
Authors: Yu-lin Ting, Yung-Yeh Su, Nai-Jung Chiang, Ying-Jui Chao, Yi-Jie Li, Chien-Jui Huang, Ting Kai Liao, Ping Jui Su, I-Ting Liu, Hui-Jen Tsai, Chia-Jui Yen, Yan-Shen Shan, Li-Tzong Chen
Journal: Annals of Oncology (2022)
P36-9 Dosimetric comparison of coplanar, non-coplanar and multi-planar VMAT for radiotherapy patients with primary brain tumor
Authors: Eva Y.W. Cheung, Dominic Y.T. Cheng, Janice K.Y. Cheng, Sapphire H.Y. Yung, Fandy Y.C. Cheng, Shirley Ng
Journal: Annals of Oncology (2022)
MO5-3 Efficacy and patient-report outcomes of atezolizumab/ bevacizumab for unresectable hepatocellular carcinoma in Thailand
Authors: Chanchai Charonpongsuntorn, Suebpong Tanasanvimon, Krittiya Korphaisarn, Songwit Payapwattanawong, Teerada Siripoon, Jitlada Juengsamarn, Ekkamol Phaibulvatanapong, Jarin Chindaprasirt, Naiyarat Prasongsook, Kittipong Udomdamrongkul, Nussara Pakvisal, Nuttapong Ngamphaiboon, Ekaphop Sirachainan
Journal: Annals of Oncology (2022)
MO43-4 The impact of nutrition support and Glasgow prognostic score in advanced gastric cancer patients treated by chemotherapy
Authors: Keiji Sugiyama, Kazuhiro Shiraishi, Takuya Motohashi, Shinpei Onoda, Riko Nishibori, Mariko Sato, Kyoko Kato, Hiroaki Uda, Masaya Suenaga, Masaaki Shimada, Noboru Hirashima, Masato Kataoka, Chiyoe Kitagawa
Journal: Annals of Oncology (2022)
P42-5 Optimal primary prophylaxis for febrile neutropenia during docetaxel, cisplatin, and 5-FU therapy for esophageal cancer
Authors: Ryosuke Kumanishi, Hiroya Taniguchi, Kyoko Kato, Taiko Nakazawa, Takatsugu Ogata, Yuki Matsubara, Hiroyuki Kodama, Akinobu Nakata, Kazunori Honda, Toshiki Masuishi, Yukiya Narita, Shigenori Kadowaki, Masashi Ando, Keiji Sugiyama, Keisaku Yamada, Sachiyo Ohnishi, Tsutomu Tanaka, Masahiro Tajika, Tetsuya Abe, Kei Muro
Journal: Annals of Oncology (2022)
MO43-3 Prognostic value of systemic inflammation score in patients treated with chemoradiotherapy for esophageal carcinoma
Authors: Kozue Kanemitsu, Yasunori Yamamoto, Masashi Hirooka, Eiji Takeshita, Yoshiou Ikeda, Bunzo Matsuura, Yoichi Hiasa
Journal: Annals of Oncology (2022)
P4-1 A retrospective analysis of outcome of chemotherapy in extra pulmonary neuroendocrine carcinoma (EP-NEC) in our hospital
Authors: Naoki Okubo, Noritoshi Kobayashi, Yuma Takeda, Akihiro Suzuki, Motohiko Tokuhisa, Yasushi Ichikawa, Yukihiko Hiroshima
Journal: Annals of Oncology (2022)
MO24-2 Clinical outcomes of tyrosine kinase inhibitors immediately after immune checkpoint inhibitors in renal cell carcinoma
Authors: Taigo Kato, Akira Nagahara, Norihiko Kawamura, Wataru Nakata, Tetsuji Soda, Kyousuke Matsuzaki, Koji Hatano, Atsunari Kawashima, Takeshi Ujike, Kensaku Nishimura, Shingo Takada, Masao Tsujihata, Seiji Yamaguchi, Tetsuya Takao, Yasutomo Nakai, Masashi Nakayama, Motohide Uemura, Norio Nonomura
Journal: Annals of Oncology (2022)
MO26-6 Short-term outcomes of induction chemotherapy followed by chemoradiotherapy in locally advanced sinonasal carcinoma
Authors: Mai Itoyama, Akihiro Ohara, Kazuki Yokoyama, Shun Yamamoto, Ken Kato, Tairo Kashihara, Naoya Murakami, Hiroshi Igaki, Yoshifumi Matsumoto, Go Omura, Seiichi Yoshimoto, Taisuke Mori, Yoshitaka Honma
Journal: Annals of Oncology (2022)
MO41-4 Clinical utility of circulating tumor DNA (ctDNA) during disease course of metastatic colorectal cancer (mCRC)
Authors: Yoojoo Lim, Sheehyun Kim, Jun-Kyu Kang, Hwang-Phil Kim, Hanseong Roh, Su Yeon Kim, Dongin Lee, Duhee Bang, Seung-Yong Jeong, Kyu Joo Park, Sae-Won Han, Tae-You Kim
Journal: Annals of Oncology (2022)
P7-4 The SERPINB7, TMEM158, and SERPINE1 signature as predictor of prognosis in patients with NSCLC after vitamin C treatment
Authors: Junwen Ou, Qiulin Liao, Yanping Du, Wentao Xi, Qiong Meng, Kexin Li, Qichun Cai, Xiufan Peng, Haijian Du, Junhua Wang, Xinting Zhang, Tao Zhang, Clifford L.K. Pang
Journal: Annals of Oncology (2022)
Persistent high-risk opioid use in lymphoma survivors following treatment.
Authors: Katherine Ann Stafford, Anita J. Kumar, Virginia Pate, Alison W. Loren, Alan Kinlaw
Journal: Journal of Clinical Oncology (2022)

6585 Background: Opioid analgesia has an important role in treating cancer pain but can place survivors at risk for long-term adverse effects, including misuse, abuse, and overdose. While opioid use has been studied in surgical oncology patients, little is known about long-term use and outcomes for patients with hematologic malignancies who primarily receive non-surgical treatment. We evaluated the association between opioid use during lymphoma treatment and persistent high-risk opioid use. Methods: We conducted a retrospective cohort study using IBM Watson Health MarketScan Commercial Claims and Encounters Data from 2000-2019, containing claims for employer-sponsored privately insured individuals in the US. We identified opioid-naïve adults age 18-64 years at their first diagnosis of Hodgkin (HL) or Non-Hodgkin lymphoma (NHL) who had outpatient cancer therapy lasting 90-240 days (including ≥3 episodes of outpatient chemotherapy). Using outpatient pharmacy claims, we categorized each patient’s opioid exposure during cancer treatment to no exposure, moderate [1-7 days supply], or high [ &gt; 7 days supply]. Follow-up began 60 days after patients’ final cancer treatment and continued up to 365 days or until an outcome or censoring event. High-risk opioid use was defined as ≥120 days cumulative supply, ≥3 consecutive months of opioid prescriptions, or a prescription with ≥90 morphine milligram equivalents per day. We used time-to-event methods to estimate cumulative incidence and hazard ratios across exposure groups. Results: There were 4380 opioid-naïve lymphoma patients in the cohort. 42.5% had HL and 57.5% had NHL. Median age at diagnosis was 46 years (IQR 32-56) and median treatment duration was 147 days (IQR 112-166). 55.0% of patients were male. During cancer treatment, 42.8% of patients had no opioid exposure, 28.1% had moderate, and 29.1% had high. Among the no-opioid-exposure group, the 1-year cumulative incidence of high-risk opioid use was 1.7%. Compared to this no-exposure group, the hazard ratios for moderate and high exposure were 2.6 (95% CI 1.5-4.6) and 9.0 (95% CI 5.6-14.4), respectively, after adjustment for cancer treatment duration, age, cancer type, and calendar time. A sensitivity analysis comparing patients diagnosed 2000-2009 vs. 2010-2019 found that hazard ratios remained consistent between the two time periods; however, there was a decrease in the absolute incidence of high-risk opioid use by approximately half. Conclusions: In this cohort study of opioid-naïve lymphoma patients, higher opioid exposure during cancer treatment was associated with a higher likelihood for persistent high-risk opioid use in the year following cancer treatment. The absolute incidence of high-risk opioid use decreased over time and may be due to increased awareness of the opioid epidemic. Close clinical follow-up in the post-treatment period may be warranted for patients at high risk of adverse outcomes.
Sequential <i>nab</i>-paclitaxel/gemcitabine followed by modified FOLFOX for first-line metastatic pancreatic cancer: The SEQUENCE trial.
Authors: Alfredo Carrato, Roberto Pazo-Cid, Teresa Macarulla, Javier Gallego, Paula Jiménez-Fonseca, Fernando Rivera, Maria Teresa Cano, Mercedes Rodríguez Garrote, Carles Pericay, Inmaculada Diaz, Laura Layos, Begoña Graña, Vega Iranzo, Inmaculada Gallego-Jimenez, Rocio Garcia-Carbonero, Maria Alvarez Alejandro, Inmaculada Ruiz de Mena, CARMEN GUILLEN PONCE, Enrique Aranda
Journal: Journal of Clinical Oncology (2022)

4022 Background: Sequential treatment with nab-paclitaxel, gemcitabine followed by oxaliplatin, leucovorin and 5-fluorouracil ( nab-P/Gem-mFOLFOX) have shown a good safety profile and clinical activity in metastatic pancreatic ductal adenocarcinoma (mPDAC) in a previously published phase I SEQUENCE trial. Methods: We have compared nab-P/Gem-mFOLFOX to the standard nab-P/Gem in first-line treatment, in an open-label multi-institutional prospective randomised phase II trial in patients with untreated mPDAC from 14 Spanish hospitals. Patients were allocated 1:1 to nab-paclitaxel (125 mg/m 2 ) plus gemcitabine (1000 mg/m 2 ) on days 1, 8 and 15, followed by modified FOLFOX-6 (oxaliplatin [85 mg/m 2 ], L-leucovorin [200 mg/m 2 ] or racemic leucovorin [400 mg/m 2 ], 5-fluorouracil bolus [400 mg/m 2 ], and 5-fluorouracil 48-hour continuous infusion [2400 mg/m 2 ]) on day 29 of a 6-week cycle or nab-paclitaxel (125 mg/m 2 ) plus gemcitabine (1000 mg/m 2 ) on days 1, 8 and 15 of a 4-week cycle. The primary endpoint was the 12-month overall survival rate (OS) in randomised patients. EudraCT number 2014-005350-19; ClinicalTrial.gov identifier NCT02504333. Results: Between July 27, 2017, and April 16, 2019, 182 patients were screened and 157 randomised: 78 to nab-P/Gem-mFOLFOX and 79 to nab-P/Gem. Patients receiving nab-P/Gem-mFOLFOX showed a significantly higher 12-month, and 24-month OS (95% CI): 55.3% (44.2-66.5%) versus 35.4% (24.9-46.0%) (p = 0.016), and 22.4% (13.0-31.8%) versus 7.6% (1.8-13.4%) (p = 0.012), respectively. The median OS (95% CI) reached 13.2 (10.1-16.2) months with nab-P/Gem-mFOLFOX and 9.7 (7.5-12.0) months with nab-P/Gem (HR = 0.676, 95% CI 0.483-0.947, p = 0.023). 39.7% patients in the nab-P/Gem-mFOLFOX group and 54.4% in nab-P/Gem group received subsequent anticancer treatments. Safety was comparable except for grade ≥3 neutropenia (46.1% versus 24.1%, p = 0.004) and grade ≥3 thrombocytopenia (23.7% versus 7.6%, p = 0.007) that were higher in the nab-P/Gem-mFOLFOX regimen. Two (2.6%) patients died due to adverse events in the nab-P/Gem-mFOLFOX arm. Conclusions: Nab-P/Gem-mFOLFOX showed significantly higher clinical activity than the standard nab-P/Gem treatment, with a manageable safety profile. This regimen represents a feasible and efficient new option for first-line treatment of mPDAC. Clinical trial information: NCT02504333.
Racial disparities in the burden of depression and anxiety in patients with pancreatic cancer.
Authors: Diana Franco, Umer Farooq, Faiz Anwer
Journal: Journal of Clinical Oncology (2022)

e16283 Background: The prevalence of depression ranges from 33% to 45% in pancreatic cancer, the highest among gastrointestinal malignancies. Psychiatric illnesses impact the quality of life and compliance with treatment and regular physician visits. Therefore, we sought to examine ethnic differences in the prevalence of depression and anxiety in pancreatic cancer. Methods: We investigated the National Inpatient Sample 2019 employing International Classification of Diseases-10 (ICD-10) codes to include adult patients with pancreatic cancer. Multivariate linear or logistic regression was used (for continuous and categorical variables, respectively). The confounders adjusted for in the regression models were: history of MI and stroke, coronary artery disease, sleep disorders, chronic pain disorders, smoking, alcohol, obesity, PTSD, sexual abuse, arthritis, and physical disability, in addition to patient and hospital-level variables. We used Stata, version 14.2, to perform analyses considering 2 sided P &lt; 0.05 as statistically significant. Results: A total of 116,055 patients with pancreatic cancer were included. 13,825 (11.91%) had depression and 16,845 (14.51%) had anxiety. The prevalence of depression in various ethnic categories was: 13.63% in Whites, 7.59% in Blacks, 8.47% in Hispanics, and 5.63% in Asians ( P&lt; 0.001). Anxiety prevalence was: 16.25% in Whites, 9.92% in Blacks, 11.65% in Hispanics, and 7.29% in Asians ( P&lt; 0.001). On multivariate analysis, compared to Whites, all ethnic groups had lower odds of depression (Blacks; adjusted odds ratio (aOR): 0.45, 95% confidence interval (CI): 0.38–0.52, P&lt; 0.001, Hispanics; aOR: 0.60, 95% CI: 0.49–0.73, P&lt; 0.001, Asians; aOR: 0.43, 95% CI: 0.31–0.59, P&lt; 0.001). Similar results were seen for anxiety when ethnic groups were compared to Whites (Blacks; aOR: 0.49, 95% CI: 0.43–0.56, P&lt; 0.001, Hispanics; aOR: 0.67, 95% CI: 0.55–0.82, P&lt; 0.001, Asians; aOR: 0.44, 95% CI: 0.33–0.59, P&lt; 0.001). Conclusions: Whites had the highest burden of depression and anxiety in pancreatic cancer. However, Hispanics represented the ethnic minority with a greater prevalence of psychiatric disorders. Further research needs to establish the factors responsible for these ethnic differences.[Table: see text]
Phase 2 study to evaluate palbociclib in combination with irinotecan and temozolomide in pediatric patients with recurrent or refractory Ewing sarcoma.
Authors: Theodore Willis Laetsch, Katherine A. Janeway, Douglas S. Hawkins, Katarzyna Juszczak-Kosela, Jodi Ann Muscal, Anderson B. Collier
Journal: Journal of Clinical Oncology (2022)

TPS11583 Background: Palbociclib (PD-0332991) is a highly selective, reversible, small molecule inhibitor of cyclin-dependent kinases (CDK) 4 and 6, administered orally. Functional dependence of Ewing Sarcoma (EWS) cell lines and tumor xenografts on Cyclin D1/CDK4 via genetic knockdown has shown both Cyclin D1 and CDK4 as critical dependencies for EWS cell line proliferation. The phase 1 portion of the study established the recommended Phase 2 dose (RP2D) with two chemotherapy backbones in children with solid tumors. The Phase 2 portion of the study now enrolls patients with EWS. The primary objective of this portion of the study is to determine whether the addition of palbociclib to irinotecan (IRN) and temozolomide (TMZ) will prolong event-free survival (EFS) of pediatric and young adult patients with recurrent or refractory EWS. Methods: Patients with recurrent or refractory EWS are randomized 2:1 to receive either palbociclib in combination with IRN and TMZ or IRN and TMZ alone. Randomization is stratified by type and time of disease recurrence (primary refractory or 1 st recurrence &lt;2 years vs. 1 st recurrence ≥2 years or 2 nd or greater recurrence). The primary efficacy endpoint is EFS per investigator assessment. Secondary efficacy endpoints include objective response, progression-free survival and overall survival. An interim futility analysis will be conducted to allow for early stopping of the study due to futility/no signal of activity based on the primary endpoint of EFS. Safety and planned interim efficacy data will be assessed by an Independent Data Monitoring Committee (DMC). Key eligibility criteria include: recurrent or refractory EWS with evaluable disease, no known bone marrow metastases, histopathological confirmation of EWSR1-ETS or FUS-ETS rearrangement or availability of formalin fixed paraffin embedded (FFPE) tumor tissue sample for central testing, age ≥2 and &lt;21 years at the time of study entry. Treatment intervention: Patients randomized to palbociclib with IRN and TMZ treatment arm will receive palbociclib at the RP2D of 75 mg/m 2 orally (either as a capsule or oral solution) once daily on Days 1-14 of each 21-day treatment cycle. TMZ will be administered orally once daily at 100 mg/m 2 on Days 1-5 (intravenously (IV) if patient cannot swallow the TMZ capsule). IRN will be administered IV at 50 mg/m 2 on Days 1-5. Patients randomized to the chemotherapy only treatment arm will receive IRN and TMZ at the same doses on Days 1-5 of the 21-day treatment cycle. Treatment will continue until disease progression, patient and/or legal guardian refusal, unacceptable toxicity , or up to 24 months of treatment, whichever occurs first. The Phase 2 enrolment has been initiated and 1/75 patients has been enrolled as of Jan 2022. Clinical trial information: NCT03709680.
Construction of a near-term predictive model for irAEs induced by PD-1 inhibitors.
Authors: Ying Zhang, Jun Zhao, Wenqing Hu, Yunyi Du, Xiaoling Zhang, Ning Ma, Wei Yang, Bo Yang, Yangjun Gao, Yu Wang, Min Liu, Mei Wang, Hui Wang, Tingting Feng, Linlin Cai, Weiling Li, Jing Lu
Journal: Journal of Clinical Oncology (2022)

3147 Background: Immune checkpoint inhibitors have opened a new chapter in cancer therapy, but the incidence of irAEs caused by them is high, and severe irAEs can be fatal. The current research on irAEs is almost focused on early predictions, and there is a lack of near-term predictions (the cycle before the occurrence of irAEs). Absolute eosinophil count (EO#) has been reported to be associated with immune-related pneumonia, but its association with other systemic irAEs requires further exploration. The aim of this study was to explore the near-term predictive value of neutrophil/lymphocyte (NLR), platelet/lymphocyte (PLR), and EO# for PD-1 inhibitor-induced irAEs. Methods: The data are from tumor patients who received PD-1 inhibitor therapy in our department from July 2019 to May 2021. A total of 146 cases were included, of which 56 had irAEs. The data of NLR, PLR and EO# in the cycle before the occurrence of irAEs (the median number of cycles was the second cycle) were collected, and the data of the second cycle was used as the control for patients without irAEs group. Logistic method was used to analyze the correlation between NLR, PLR and EO# and irAEs, and a predictive model was constructed. The sensitivity and specificity of the model were evaluated by ROC curve. This study was registered on Chinese Clinical Trail Registry (ChiCTR2100049849). Results: A total of 146 tumor patients were included, of which 56 developed at least one irAEs. Grade 1-2 irAEs occurred in 39 cases, grade 3-4 in 12 cases (including cardiac, liver, lung and skin toxicity), grade 5 in 2 cases(including cardiac and lung toxicity), and ungraded in 3 cases. The data of the cycle before the occurrence of irAEs were analyzed. Univariate analysis showed that NLR (odds ratio [OR], 1.4, p&lt; 0.05) and EO# (OR, 12.6, p&lt; 0.05) were associated with irAEs, and multivariate analysis suggested NLR (OR, 1.7, p&lt; 0.001) and EO# (OR, 20.4, p&lt; 0.05) were independent risk factors for irAEs. The prediction model composed of NLR, PLR and EO# had a correct rate of 76.7% (AUC = 0.752) in predicting the occurrence of irAEs in the near-term cycle, with a sensitivity of 51.8% and a specificity of 92.2%; the correct rate of predicting irAEs of grade 3 and above was as high as 91.9% (AUC = 0.778), the sensitivity was 14.3% and the specificity was 99.2%. Conclusions: The model composed of NLR, PLR and EO# may predict the occurrence of irAEs in the near-term cycle, especially the prediction of irAEs above grade 3, which can provide early warning for the occurrence of irAEs. Clinical trial information: ChiCTR2100049849.
Neoadjuvant attelizumab combined chemotherapy in limited-stage and resectable small cell lung cancer: A multicentric, single-arm and open study.
Authors: Xiaolong Yan, Hongtao Duan, Liang Shi, Hongxia Li, Liping Tong, Zhe Liu
Journal: Journal of Clinical Oncology (2022)

e20615 Background: Combine chemotherapy and immunotherapy have become the first-line treatment program for extensive small cell lung cancer. The aim of this study is to explore the safety and efficacy of neoadjuvant chemotherapy and immunotherapy in limited-stage small cell lung cancer. Methods: Treatment-naïve patients were enrolled and the patients received the 2-3 cycles of neoadjuvent chemotherapy and atezolizumab (1200mg, D1). surgery was performed within 4-6 weeks after the last treatment. The primary endpoint was surgery patients pathological complete response (PCR). Safety was assessed by adverse events (AEs) and postoperative complications. This trial was registered at the Chinese Clinical Trial Registry (Registration Number: (ChiCTR2100042367). Results: Recruitment started in May 2020. We reported 9 patients with neoadjuvent immunochemotherapy who have completed surgical treatment. Baseline characteristics: 7 males, with an average age of 52.1 years old, all ECOG PS 0-1; 6 current smokers; clinical stages IIB / IIIA / IIIB n = 6 / 1 / 2. There were 1 atezolizumab treatment-related Gr1 AEs (rush) and 4 treatment-related Gr 3-4 AEs. According to Recist 1.1, all patients achieved partial response. 9 patients completed surgery, 3 patients received bilobectomy, and 3 patients underwent pneumonectomy. Surgical methods included robot-assisted thoracoscopic surgery (RATS) /video-assisted thoracoscopic surgery (VATS) (3, 33.3%) and thoracotomy (6, 66.7%). Complete resection (R0) was achieved in 100% of patients (9/9). The mean operation time was 136 min; the mean bleeding volume was 194.4ml, and the mean hospital stay was 8.9 days. The postoperative pathology results showed a PCR (66.7%) in 6 patients and a MPR (88.9%) in 8 patients. Conclusions: Neoadjuvant chemotherapy and atezolizumab therapy significantly improves PCR in small cell lung cancer without unknown AE events and no surgical delay, so this protocol is safe and feasible. Whether the survival benefit is still unknown. Keywords: neoadjuvant therapy, Small cell lung cancer, immunotherapy, surgery, PCR. Clinical trial information: ChiCTR2100042367. [Table: see text]